Back to top

biotechs: Archive

Zacks Equity Research

Bayer Wins FDA Approval for Sunharbo for Secondary Stroke Risk Reduction

Bayer gains FDA approval for Sunharbo, the first Factor XIa inhibitor approved worldwide, opening new growth opportunities in stroke prevention.

BAYRYNegative Net Change REGNNegative Net Change JNJNegative Net Change

Zacks Equity Research

TGTX Q3 Earnings & Revenues Beat Estimates, 2026 View Raised, Stock Up

TG Therapeutics beats Q3 earnings and revenue estimates as Briumvi demand accelerates, shares rise 5.9%, and 2026 revenue guidance climbs to $1 billion.

TGTXNegative Net Change HALONegative Net Change COLLPositive Net Change AMRXNegative Net Change

Zacks Equity Research

CRMD to Acquire HRTX Assets for $223M Upfront to Expand Portfolio

CorMedix is set to acquire HRTX's commercial assets for $223 million upfront, adding four products, expanding its hospital reach and targeting significant cost synergies.

CRMDPositive Net Change TGTXNegative Net Change HRTXNegative Net Change AMRXNegative Net Change

Ahan Chakraborty

4 Commercial-Stage Biotechs Poised for Sustained Revenue Growth

TGTX, BCRX, INSM and MDGL are expanding product sales through rising demand, broader patient access and new market opportunities.

BCRXNegative Net Change INSMPositive Net Change TGTXNegative Net Change MDGLNegative Net Change

Sundeep Ganoria

Can Moderna's First Cancer Therapy Win FDA Approval in 2027?

MRNA targets a year-end 2026 FDA filing for its personalized cancer therapy, intismeran, potentially paving the way for a regulatory decision in 2027.

MRNANegative Net Change SNYPositive Net Change PFENegative Net Change MRKNegative Net Change

Ahan Chakraborty

Novo Up 4% in a Month: How Should Investors Approach the Stock Now?

NVO gains 4% in a month on strong Q3 Wegovy pill sales and raised guidance, but intensifying competition and pricing pressures cloud its growth outlook.

NVONegative Net Change LLYNegative Net Change VKTXNegative Net Change GPCRNegative Net Change

Ekta Bagri

Will Bristol Myers' Growth Brands Offset Eliquis Headwinds?

Bristol Myers' Growth Portfolio drives 57% of revenues, with key brands gaining traction to offset legacy drug declines and support growth.

BMYNegative Net Change PFENegative Net Change MRKNegative Net Change

Shaun Pruitt

Moderna (MRNA) Stock Hits 52-Week Highs After Q3 Earnings: Buy, Hold, or Sell?

Moderna stock has surged as much as 10% in Friday's trading session, reaching a fresh 52-week high after delivering much stronger-than-expected Q3 results.

MRNANegative Net Change MRKNegative Net Change LLYNegative Net Change ABBVNegative Net Change

Zacks Equity Research

MRNA Q3 Earnings Beat on COVID Sales, Raises '26 Outlook, Stock Rises

Moderna's Q3 earnings beat estimates on strong COVID-19 vaccine sales, returning to profitability and boosting its 2026 revenue growth outlook.

MRNANegative Net Change MRKNegative Net Change ABUSNegative Net Change

Zacks Equity Research

Halozyme Stock Down Despite Q3 Earnings and Revenue Beat

HALO's Q3 earnings & revenues beat estimates, driven by higher royalties and product sales. The company raises its 2026 outlook, yet shares fall in after-hours.

HALONegative Net Change RHHBYPositive Net Change JNJNegative Net Change ARGXNegative Net Change